```html

Visceral Leishmaniasis – A Complete Patient‑Focused Guide

Overview

Visceral leishmaniasis (VL), also called kala‑azar, is a systemic parasitic disease caused by the protozoan Leishmania donovani complex (primarily L. donovani and L. infantum/L. chagasi). The parasites are transmitted to humans by the bite of infected female sand‑flies (genus Phlebotomus in the Old World and Lutzomyia in the New World).

• Who it affects: VL most commonly occurs in children and adults with prolonged exposure to sand‑fly habitats—rural, impoverished communities with poor housing and limited access to health care.
• Geographic prevalence: Endemic in 78 countries across South Asia, East Africa, the Mediterranean, and parts of Brazil. The World Health Organization (WHO) estimates 50,000–90,000 new cases each year, with >95 % of cases reported from India, Bangladesh, Nepal, Sudan, Ethiopia, and Brazil [WHO].
• Public‑health impact: Without treatment, mortality can reach 95 % within two years of symptom onset [CDC]. The disease contributes to cycles of poverty because it disproportionately affects the most socio‑economically vulnerable populations.

Symptoms

Symptoms develop 2–6 months after infection (sometimes up to a year). The classic triad is prolonged fever, splenomegaly, and weight loss, but many additional signs may appear.

• Fever: Persistent, often irregular, and may be higher in the evenings.
• Weight loss & cachexia: Marked loss of body mass despite normal or reduced appetite.
• Hepatosplenomegaly: Enlargement of the liver and, especially, the spleen, causing a sense of fullness or early satiety.
• Fatigue & weakness: Generalized exhaustion that interferes with daily activities.
• Anemia: Pale skin, shortness of breath on exertion, and tachycardia.
• Leukopenia & thrombocytopenia: Increased susceptibility to infections and easy bruising or bleeding.
• Hyperpigmentation: Darkening of the skin, especially on the face and arms (more common in Indian patients).
• Focal skin lesions (post‑kala‑azar dermal leishmaniasis, PKDL): Small papules or nodules that appear months to years after successful VL treatment, mainly in South Asia.
• Fever spikes after meals or during travel: May mimic malaria; key to ask about sand‑fly exposure.

Causes and Risk Factors

Pathophysiology

When an infected sand‑fly takes a blood meal, it injects promastigotes into the skin. Inside macrophages, the parasites transform into amastigotes, replicate, and disseminate via the bloodstream to the reticuloendothelial system (spleen, liver, bone marrow). Their proliferation impairs normal immune function, leading to the hematologic abnormalities seen in VL.

Major Risk Factors

• Geographic exposure: Living or traveling in endemic rural areas, especially near forests, termite mounds, or animal shelters.
• Poverty and substandard housing: Mud walls, thatched roofs, and lack of window screens increase sand‑fly contact.
• Malnutrition: Impaired cell‑mediated immunity lowers resistance.
• Immunosuppression: HIV infection, organ transplantation, or chronic corticosteroid use markedly raises risk and can accelerate disease progression.
• Age: Children under 12 and the elderly are more vulnerable because of weaker immune defenses.
• Animal reservoirs: In Mediterranean and Latin American regions, domestic dogs are the main reservoir for L. infantum; close contact with infected dogs raises human risk.

Diagnosis

Early and accurate diagnosis is essential because delayed treatment significantly raises mortality. Diagnosis combines clinical suspicion with laboratory confirmation.

Primary Diagnostic Tests

1. Serologic tests – Detect antibodies against Leishmania antigens.
   • rK39 rapid diagnostic test (RDT) – Simple finger‑stick test; sensitivity 90–95 % in Indian subcontinent, slightly lower (~85 %) in East Africa [CDC].
   • Direct Agglutination Test (DAT) – Laboratory‑based; high specificity but requires serum processing.
2. Microscopy – Visualizing amastigotes in tissue aspirates.
   • Bone‑marrow or splenic aspirates are most sensitive (≈95 %); however, splenic aspirates carry a small risk of bleeding.
3. Polymerase Chain Reaction (PCR) – Detects parasite DNA in blood, bone‑marrow, or tissue. Provides >98 % sensitivity and can differentiate species, guiding therapy.
4. Culture – Inoculation of aspirate into Novy‑MacNeal‑Nicolle (NNN) medium; rarely used because it is slow (2–4 weeks).

Additional Laboratory Findings

• Complete blood count: anemia, leukopenia, thrombocytopenia.
• Liver function tests: elevated transaminases, low albumin.
• Elevated inflammatory markers (ESR, CRP).

When to Perform Tests

If a patient has lived/traveled in an endemic area and presents with fever >2 weeks plus splenomegaly or unexplained cytopenias, initiate serology (rK39) while arranging confirmatory microscopy or PCR.

Treatment Options

Treatment regimens differ by region, parasite species, patient age, pregnancy status, and co‑existing HIV infection. The goal is to achieve parasitologic cure while minimizing toxicity.

First‑Line Antileishmanial Drugs

1. Liposomal Amphotericin B (AmBisome)
   • Dosage: 3 mg/kg on days 1–5, 14, and 21 (total 21 mg/kg) – WHO recommended single‑course regimen for South Asia.
   • Advantages: High cure rates (>95 %) and lower nephrotoxicity than conventional amphotericin B.
   • Side effects: Infusion‑related fever, chills, hypokalemia; monitor renal function.
2. Miltefosine (Impavido)
   • Oral agent; 2.5 mg/kg/day (max 150 mg) for 28 days.
   • Convenient for outpatient care; cure rates 94 % in India.
   • Contra‑indicated in pregnancy (teratogenic) and requires renal/hepatic monitoring.
3. Paromomycin (Pentostam)
   • Intra‑muscular injection, 11 mg/kg daily for 21 days (India) or 20 days (East Africa).
   • Effective (85–90 % cure) but can cause injection‑site pain and ototoxicity at high cumulative doses.
    

Combination Therapy (for HIV‑co‑infection or relapsed disease)

• Liposomal amphotericin B + miltefosine or paromomycin – improves efficacy and reduces resistance risk.
• Therapy duration may be extended to 4–6 weeks, with secondary prophylaxis (e.g., monthly AmBisome) for HIV‑positive patients [CDC HIV].

Supportive Care & Lifestyle Measures

• Correct anemia with iron/folic acid supplementation.
• Transfuse platelets or red cells if counts fall dangerously low.
• Nutrition: high‑protein, energy‑dense diet; treat malnutrition aggressively.
• Manage fever with acetaminophen; avoid NSAIDs if renal function is compromised.

Living with Visceral Leishmaniasis

Even after successful treatment, many patients require ongoing monitoring and lifestyle adjustments.

• Follow‑up schedule: Clinical review at 1, 3, 6, and 12 months post‑therapy; repeat serology or PCR if relapse is suspected.
• Nutrition: Daily intake of 2500–3000 kcal, rich in protein (eggs, beans, lean meat) and micronutrients (vitamins A, C, zinc).
• Hygiene & infection prevention: Hand washing, safe food storage, and prompt treatment of secondary bacterial infections.
• Vaccination: Keep immunizations up‑to‑date (especially pneumococcal, Hib, and influenza) to lower the risk of opportunistic infections.
• Psychosocial support: Chronic disease and stigma can cause anxiety or depression; seek community health workers or counseling services.
• Pregnancy considerations: Women of child‑bearing age should discuss treatment timing; liposomal amphotericin B is preferred during pregnancy because miltefosine is teratogenic.

Prevention

Because VL is vector‑borne, prevention focuses on reducing sand‑fly contact and limiting animal reservoirs.

1. Vector control
   • Indoor residual spraying (IRS) with insecticide (e.g., pyrethroids) before sand‑fly season.
   • Use of long‑lasting insecticidal nets (LLINs) – especially for sleeping in huts without windows.
   • Environmental management: fill cracks in walls, clear vegetation, and remove animal dung piles near homes.
2. Personal protection
   • Wear long sleeves, trousers, and closed shoes from dusk to dawn.
   • Apply repellents containing DEET (20‑30 %) or picaridin on exposed skin.
3. Animal reservoir control (Mediterranean & Latin America)
   • Screen and treat infected dogs with topical insecticides or systemic antileishmanial drugs.
   • Vaccinate dogs where licensed (e.g., Leish-Tec in Brazil).
4. Health‑system measures
   • Active case detection in endemic villages – mobile clinics and community health volunteers.
   • Rapid diagnostic test kits in primary‑care settings to enable early treatment.

Complications

If left untreated or inadequately treated, VL can cause life‑threatening complications:

• Severe anemia, leukopenia, and thrombocytopenia leading to hemorrhage and secondary infections.
• Hepatosplenomegaly‑related rupture – rare but catastrophic splenic rupture.
• Post‑kala‑azar dermal leishmaniasis (PKDL) – chronic skin lesions that may serve as a reservoir for transmission.
• HIV co‑infection – accelerates disease progression; patients have higher relapse rates (up to 60 % within 2 years).
• Malnutrition and growth retardation in children.
• Organ failure – renal, hepatic, or cardiac dysfunction from both disease and drug toxicity.

When to Seek Emergency Care

---

For personalized advice, always consult a qualified health professional. This guide is for educational purposes and does not replace professional diagnosis or treatment.

```